TY - JOUR T1 - Role of alendronate and risedronate in preventing and treating osteoporosis JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 945 LP - 951 VL - 68 IS - 11 AU - Margaret L. Peters AU - Mandy Leonard AU - Angelo A. Licata Y1 - 2001/11/01 UR - http://www.ccjm.org/content/68/11/945.abstract N2 - Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication. ER -